The ability of adenoviruses to persist in lymphoid tissues and their propensity for reactivation in immunocompromised patients complicate management and necessitate ongoing research for effective vaccines and therapies. Our company offers a comprehensive suite of services for adenovirus infection vaccines and therapies development.
Introduction to Adenovirus Infection
Adenoviruses (AdVs) represent a diverse category of double-stranded DNA viruses that give rise to various illnesses in humans. These viruses are accountable for respiratory infections, conjunctivitis, gastroenteritis, and more serious conditions in individuals with compromised immune systems. Common transmission routes include respiratory droplets, direct contact with contaminated surfaces, and oral-fecal spread. While infections typically present as mild respiratory ailments, they can escalate to severe complications, especially in young children and immunocompromised individuals.
Fig.1 Tropism of human adenoviruses with associated clinical diseases in various organ systems. (Shieh W. J., et al., 2022)
Vaccine Development for Adenovirus Infection
The development of vaccines against adenovirus infections is a critical area of research, focusing on creating immunogenic responses that prevent or mitigate disease severity. Several types of vaccines are being explored:
Live Attenuated Vaccines
These vaccines use live viruses that have been weakened so they do not cause disease. They have been used in the military to protect against respiratory infections caused by AdV types 4 and 7.
Recombinant Vector Vaccines
Utilizing a harmless virus as a vector to deliver specific antigens of adenoviruses, these vaccines aim to stimulate an immune response without causing the disease.
Subunit Vaccines
These vaccines use purified pieces of the virus, such as proteins or sugars, to elicit an immune response. They are considered safe as they do not contain live virus.
DNA Vaccines
Involving the use of plasmids encoding for adenovirus antigens, these vaccines are at the forefront of modern vaccine development and can induce both cellular and humoral immune responses.
mRNA Vaccines
A novel approach in vaccine development, mRNA vaccines introduce the genetic code for specific adenovirus antigens, allowing the host cells to produce these proteins and stimulate an immune response.
Inactivated Vaccines
Inactivated vaccines, though less common for adenoviruses, are being explored. These vaccines involve the use of killed adenovirus particles to stimulate an immune response without causing disease.
Therapeutics Development for Adenovirus Infection
Cidofovir is a cytosine nucleotide analog that has shown in vitro activity against adenoviruses. It inhibits viral DNA synthesis and is used off-label for severe infections. In addition, nucleoside analogs, such as brincidofovir, are modified versions of nucleosides that can be incorporated into viral DNA, thereby inhibiting replication. Our company is capable of providing you with antiviral drugs and immunotherapy for novel adenovirus infections. You can click on the following link to learn about our one-stop solution.
Our Services
With a multidisciplinary team of seasoned experts, we merge state-of-the-art research with hands-on applications to craft and execute groundbreaking adenovirus infection vaccine and therapeutics development solutions. We focus on:
Disease Models
- Acute Respiratory Disease Models with Murine Adenovirus
- Adenovirus Infection Pig Models: mimic interstitial pneumonia in humans
- Adenovirus Keratoconjunctivitis New Zealand White Rabbit Models
- Adenovirus-C5 Lung and Ocular Infection Cotton Rat Models
Through our integrated approach, we aim to accelerate the discovery and development of effective vaccines and therapies against adenovirus infections. If you are interested in our services, please feel free to contact us.
References
- Shieh, Wun-Ju. "Human adenovirus infections in pediatric population-an update on clinico-pathologic correlation." Biomedical journal 45.1 (2022): 38-49.
- Lynch III, Joseph P., and Adriana E. Kajon. "Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention." Seminars in respiratory and critical care medicine. Vol. 37. No. 04. Thieme Medical Publishers, 2016.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
